Kim Kuypers
Associate Professor of Psychopharmacology
Data updated
Research Footprint
Kim Kuypers appears in 54 tracked papers (2005–2026), most studied alongside Psilocybin, LSD and MDMA, across Depressive Disorders, Microdosing and Healthy Volunteers.
Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).
Frequent co-authors: Johannes Ramaekers, Nathalie Mason and Eline Theunissen.
Publication Landscape
How the 54 papers Blossom tracks for Kim Kuypers line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Kim Kuypers's publishing grown?
SourcedTracked papers by publication year; 4 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 54 of 54 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Kim Kuypers publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Kim Kuypers publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Kim P. C. Kuypers is an Associate Professor at Maastricht University, specialising in the psychopharmacological properties of psychedelics and their applications in mental health. Her research extensively explores the impacts of various psychedelics, including lysergic acid diethylamide (LSD), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and MDMA, on behaviour and psychological wellbeing. Noteworthy contributions include studies demonstrating the effects of microdosing psychedelics on pain perception and life satisfaction, as well as investigating the drug-induced alterations in cognitive functions. Additionally, she has developed innovative research paradigms to deepen the understanding of psychedelic use motives and experienced effects, marking significant advancements in the scientific study of psychedelics.
Key Impact
Kuypers is a leading figure in psychedelic research, particularly in understanding the effects of psychedelics on pain perception and mental health.
Collaboration Network
54 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Kim Kuypers's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Kim Kuypers is associated with.
Maastricht University
academicAssociate Professor
While Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.
View stakeholder →Clerkenwell Health
UK psychedelic and CNS trial infrastructure provider with specialist trial sites, sponsor-facing psychiatric research support, recruitment pathways, and therapist-related trial expertise.
View stakeholder →